Leukemia-initiating cells in T-cell acute lymphoblastic leukemia

Frontiers in Oncology

Volumn 7, Issue SEP, 2017, Pages

  Tan, Shi Hao ^a   Bertulfo, Fatima Carla ^a   Sanda, Takaomi ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Dept Medicine Endocrinol Diabet   (Singapore)

Author keywords

Core regulatory circuit; Leukemia initiating cells; NOTCH1; T cell acute lymphoblastic leukemia; TAL1

Indexed keywords

CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; ICN1 PROTEIN; NOTCH1 RECEPTOR; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN MYB; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR LMO2; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR TAL1; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOID LEUKEMIA; CANCER STEM CELL; CARCINOGENESIS; CELL DIFFERENTIATION; DNA TRANSCRIPTION; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; INTRACELLULAR SIGNALING; LEUKEMIA INITIATING CELL; MOLECULAR PATHOLOGY; MUTATION; NONHUMAN; REVIEW; THYMOCYTE; TUMOR MICROENVIRONMENT;

EID: 85029855315     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2017.00218     Document Type: Review

References (123)

1. Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell (2014) 14(3):275-91. doi:10.1016/j.stem.2014.02.006
2. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med (2011) 17(3):313-9. doi:10.1038/nm.2304
3. Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells - what challenges do they pose Nat Rev Drug Discov (2014) 13(7):497-512. doi:10.1038/nrd4253
4. Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer (2012) 12(2):133-43. doi:10.1038/nrc3184
5. Cox CV, Martin HM, Kearns PR, Virgo P, Evely RS, Blair A. Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia. Blood (2007) 109(2):674-82. doi:10.1182/blood-2006-06-030445
6. Gerby B, Clappier E, Armstrong F, Deswarte C, Calvo J, Poglio S, et al. Expression of CD34 and CD7 on human T-cell acute lymphoblastic leukemia discriminates functionally heterogeneous cell populations. Leukemia (2011) 25(8):1249-58. doi:10.1038/leu.2011.93
7. Chiu PP, Jiang H, Dick JE. Leukemia-initiating cells in human T-lymphoblastic leukemia exhibit glucocorticoid resistance. Blood (2010) 116(24):5268-79. doi:10.1182/blood-2010-06-292300
8. Tremblay M, Tremblay CS, Herblot S, Aplan PD, Hébert J, Perreault C, et al. Modeling T-cell acute lymphoblastic leukemia induced by the SCL and LMO1 oncogenes. Genes Dev (2010) 24(11):1093-105. doi:10.1101/gad.1897910
9. Tatarek J, Cullion K, Ashworth T, Gerstein R, Aster JC, Kelliher MA. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL. Blood (2011) 118(6):1579-90. doi:10.1182/blood-2010-08-300343
10. O'Neil J, Shank J, Cusson N, Murre C, Kelliher M. TAL1/SCL induces leukemia by inhibiting the transcriptional activity of E47/HEB. Cancer Cell (2004) 5(6):587-96. doi:10.1016/j.ccr.2004.05.023
11. McCormack MP, Young LF, Vasudevan S, de Graaf CA, Codrington R, Rabbitts TH, et al. The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal. Science (2010) 327(5967):879-83. doi:10.1126/science.1182378
12. Gerby B, Tremblay CS, Tremblay M, Rojas-Sutterlin S, Herblot S, Hébert J, et al. SCL, LMO1 and Notch1 reprogram thymocytes into self-renewing cells. PLoS Genet (2014) 10(12):e1004768. doi:10.1371/journal.pgen.1004768
13. Aifantis I, Raetz E, Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol (2008) 8(5):380-90. doi:10.1038/nri2304
14. Belver L, Ferrando A. The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer (2016) 16(8):494-507. doi:10.1038/nrc.2016.63
15. Iacobucci I, Mullighan CG. Genetic basis of acute lymphoblastic leukemia. J Clin Oncol (2017) 35(9):975-83. doi:10.1200/JCO.2016.70.7836
16. Look AT. Oncogenic transcription factors in the human acute leukemias. Science (1997) 278(5340):1059-64. doi:10.1126/science.278.5340.1059
17. Martins VC, Ruggiero E, Schlenner SM, Madan V, Schmidt M, Fink PJ, et al. Thymus-autonomous T cell development in the absence of progenitor import. J Exp Med (2012) 209(8):1409-17. doi:10.1084/jem.20120846
18. Peaudecerf L, Lemos S, Galgano A, Krenn G, Vasseur F, Di Santo JP, et al. Thymocytes may persist and differentiate without any input from bone marrow progenitors. J Exp Med (2012) 209(8):1401-8. doi:10.1084/jem.20120845
19. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet (2008) 371(9617):1030-43. doi:10.1016/S0140-6736(08)60457-2
20. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol (2011) 29(5):551-65. doi:10.1200/JCO.2010.30.7405
21. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol (2011) 29(5):532-43. doi:10.1200/JCO.2010.30.1382
22. Nguyen K, Devidas M, Cheng SC, La M, Raetz EA, Carroll WL, et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia (2008) 22(12):2142-50. doi:10.1038/leu.2008.251
23. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature (2014) 505(7484):495-501. doi:10.1038/nature12912
24. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature (2013) 500(7463):415-21. doi:10.1038/nature12477
25. Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol (2005) 23(26):6306-15. doi:10.1200/JCO.2005.05.047
26. Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell (2002) 1(1):75-87. doi:10.1016/S1535-6108(02)00018-1
27. Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson MR, et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet (2017) 49(8):1211-8. doi:10.1038/ng.3909
28. Porcher C, Liao EC, Fujiwara Y, Zon LI, Orkin SH. Specification of hematopoietic and vascular development by the bHLH transcription factor SCL without direct DNA binding. Development (1999) 126(20):4603-15.
29. Shivdasani RA, Mayer EL, Orkin SH. Absence of blood formation in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL. Nature (1995) 373(6513):432-4. doi:10.1038/373432a0
30. Warren AJ, Colledge WH, Carlton MB, Evans MJ, Smith AJ, Rabbitts TH. The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development. Cell (1994) 78(1):45-57. doi:10.1016/0092-8674(94)90571-1
31. Capron C, Lecluse Y, Kaushik AL, Foudi A, Lacout C, Sekkai D, et al. The SCL relative LYL-1 is required for fetal and adult hematopoietic stem cell function and B-cell differentiation. Blood (2006) 107(12):4678-86. doi:10.1182/blood-2005-08-3145
32. Chambers J, Rabbitts TH. LMO2 at 25 years: a paradigm of chromosomal translocation proteins. Open Biol (2015) 5(6):150062. doi:10.1098/rsob.150062
33. Porcher C, Chagraoui H, Kristiansen MS. SCL/TAL1: a multifaceted regulator from blood development to disease. Blood (2017) 129(15):2051-60. doi:10.1182/blood-2016-12-754051
34. Kelliher MA, Seldin DC, Leder P. Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase IIalpha. EMBO J (1996) 15(19):5160-6.
35. Aplan PD, Jones CA, Chervinsky DS, Zhao X, Ellsworth M, Wu C, et al. An scl gene product lacking the transactivation domain induces bony abnormalities and cooperates with LMO1 to generate T-cell malignancies in transgenic mice. EMBO J (1997) 16(9):2408-19. doi:10.1093/emboj/16.9.2408
36. Begley CG, Aplan PD, Davey MP, Nakahara K, Tchorz K, Kurtzberg J, et al. Chromosomal translocation in a human leukemic stem-cell line disrupts the T-cell antigen receptor delta-chain diversity region and results in a previously unreported fusion transcript. Proc Natl Acad Sci U S A (1989) 86(6):2031-5. doi:10.1073/pnas.86.6.2031
37. Breit TM, Mol EJ, Wolvers-Tettero IL, Ludwig WD, van Wering ER, van Dongen JJ. Site-specific deletions involving the tal-1 and sil genes are restricted to cells of the T cell receptor alpha/beta lineage: T cell receptor delta gene deletion mechanism affects multiple genes. J Exp Med (1993) 177(4):965-77. doi:10.1084/jem.177.4.965
38. Mansour MR, Abraham BJ, Anders L, Berezovskaya A, Gutierrez A, Durbin AD, et al. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science (2014) 346(6215):1373-7. doi:10.1126/science.1259037
39. Roberts CW, Shutter JR, Korsmeyer SJ. Hox11 controls the genesis of the spleen. Nature (1994) 368(6473):747-9. doi:10.1038/368747a0
40. De Keersmaecker K, Real PJ, Gatta GD, Palomero T, Sulis ML, Tosello V, et al. The TLX1 oncogene drives aneuploidy in T cell transformation. Nat Med (2010) 16(11):1321-7. doi:10.1038/nm.2246
41. Alharbi RA, Pettengell R, Pandha HS, Morgan R. The role of HOX genes in normal hematopoiesis and acute leukemia. Leukemia (2013) 27(5):1000-8. doi:10.1038/leu.2012.356
42. Dik WA, Brahim W, Braun C, Asnafi V, Dastugue N, Bernard OA, et al. CALM-AF10+ T-ALL expression profiles are characterized by overexpression of HOXA and BMI1 oncogenes. Leukemia (2005) 19(11):1948-57. doi:10.1038/sj.leu.2403891
43. Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol (2009) 10(2):147-56. doi:10.1016/S1470-2045(08)70314-0
44. Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 306(5694):269-71. doi:10.1126/science.1102160
45. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell (1991) 66(4):649-61. doi:10.1016/0092-8674(91)90111-B
46. O'Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C, et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med (2007) 204(8):1813-24. doi:10.1084/jem.20070876
47. Thompson BJ, Buonamici S, Sulis ML, Palomero T, Vilimas T, Basso G, et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med (2007) 204(8):1825-35. doi:10.1084/jem.20070872
48. Pear WS, Aster JC, Scott ML, Hasserjian RP, Soffer B, Sklar J, et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med (1996) 183(5):2283-91. doi:10.1084/jem.183.5.2283
49. Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A, et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A (2006) 103(48):18261-6. doi:10.1073/pnas.0606108103
50. Wendorff AA, Koch U, Wunderlich FT, Wirth S, Dubey C, Brüning JC, et al. Hes1 is a critical but context-dependent mediator of canonical Notch signaling in lymphocyte development and transformation. Immunity (2010) 33(5):671-84. doi:10.1016/j.immuni.2010.11.014
51. Sharma VM, Calvo JA, Draheim KM, Cunningham LA, Hermance N, Beverly L, et al. Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc. Mol Cell Biol (2006) 26(21):8022-31. doi:10.1128/MCB.01091-06
52. Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, Wai C, et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev (2006) 20(15):2096-109. doi:10.1101/gad.1450406
53. Sanda T, Li X, Gutierrez A, Ahn Y, Neuberg DS, O'Neil J, et al. Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia. Blood (2010) 115(9):1735-45. doi:10.1182/blood-2009-07-235143
54. Ntziachristos P, Tsirigos A, Van Vlierberghe P, Nedjic J, Trimarchi T, Flaherty MS, et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med (2012) 18(2):298-301. doi:10.1038/nm.2651
55. Ntziachristos P, Tsirigos A, Welstead GG, Trimarchi T, Bakogianni S, Xu L, et al. Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature (2014) 514(7523):513-7. doi:10.1038/nature13605
56. Van der Meulen J, Sanghvi V, Mavrakis K, Durinck K, Fang F, Matthijssens F, et al. The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. Blood (2015) 125(1):13-21. doi:10.1182/blood-2014-05-577270
57. Benyoucef A, Palii CG, Wang C, Porter CJ, Chu A, Dai F, et al. UTX inhibition as selective epigenetic therapy against TAL1-driven T-cell acute lymphoblastic leukemia. Genes Dev (2016) 30(5):508-21. doi:10.1101/gad.276790.115
58. Seki M, Kimura S, Isobe T, Yoshida K, Ueno H, Nakajima-Takagi Y, et al. Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia. Nat Genet (2017) 49(8):1274-81. doi:10.1038/ng.3900
59. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res (2006) 66(19):9339-44. doi:10.1158/0008-5472.CAN-06-3126
60. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature (1994) 367(6464):645-8. doi:10.1038/367645a0
61. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med (1997) 3(7):730-7. doi:10.1038/nm0797-730
62. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 100(7):3983-8. doi:10.1073/pnas.0530291100
63. Visvader JE. Cells of origin in cancer. Nature (2011) 469(7330):314-22. doi:10.1038/nature09781
64. Sarry JE, Murphy K, Perry R, Sanchez PV, Secreto A, Keefer C, et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2R?c-deficient mice. J Clin Invest (2011) 121(1):384-95. doi:10.1172/JCI41495
65. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science (2007) 317(5836):337. doi:10.1126/science.1142596
66. Cox CV, Evely RS, Oakhill A, Pamphilon DH, Goulden NJ, Blair A. Characterization of acute lymphoblastic leukemia progenitor cells. Blood (2004) 104(9):2919-25. doi:10.1182/blood-2004-03-0901
67. Cox CV, Diamanti P, Evely RS, Kearns PR, Blair A. Expression of CD133 on leukemia-initiating cells in childhood ALL. Blood (2009) 113(14):3287-96. doi:10.1182/blood-2008-04-154187
68. Castor A, Nilsson L, Astrand-Grundström I, Buitenhuis M, Ramirez C, Anderson K, et al. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med (2005) 11(6):630-7. doi:10.1038/nm1253
69. Bardini M, Woll PS, Corral L, Luc S, Wittmann L, Ma Z, et al. Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement. Leukemia (2015) 29(1):38-50. doi:10.1038/leu.2014.154
70. O'Neil J, Calvo J, McKenna K, Krishnamoorthy V, Aster JC, Bassing CH, et al. Activating Notch1 mutations in mouse models of T-ALL. Blood (2006) 107(2):781-5. doi:10.1182/blood-2005-06-2553
71. Cui Y, Onozawa M, Garber HR, Samsel L, Wang Z, McCoy JP, et al. Thymic expression of a T-cell receptor targeting a tumor-associated antigen coexpressed in the thymus induces T-ALL. Blood (2015) 125(19):2958-67. doi:10.1182/blood-2014-10-609271
72. Chiang MY, Shestova O, Xu L, Aster JC, Pear WS. Divergent effects of supraphysiologic Notch signals on leukemia stem cells and hematopoietic stem cells. Blood (2013) 121(6):905-17. doi:10.1182/blood-2012-03-416503
73. Guo W, Lasky JL, Chang CJ, Mosessian S, Lewis X, Xiao Y, et al. Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature (2008) 453(7194):529-33. doi:10.1038/nature06933
74. Schubbert S, Cardenas A, Chen H, Garcia C, Guo W, Bradner J, et al. Targeting the MYC and PI3K pathways eliminates leukemia-initiating cells in T-cell acute lymphoblastic leukemia. Cancer Res (2014) 74(23):7048-59. doi:10.1158/0008-5472.CAN-14-1470
75. Langenau DM, Feng H, Berghmans S, Kanki JP, Kutok JL, Look AT. Cre/lox-regulated transgenic zebrafish model with conditional myc-induced T cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2005) 102(17):6068-73. doi:10.1073/pnas.0408708102
76. Smith AC, Raimondi AR, Salthouse CD, Ignatius MS, Blackburn JS, Mizgirev IV, et al. High-throughput cell transplantation establishes that tumor-initiating cells are abundant in zebrafish T-cell acute lymphoblastic leukemia. Blood (2010) 115(16):3296-303. doi:10.1182/blood-2009-10-246488
77. Blackburn JS, Liu S, Wilder JL, Dobrinski KP, Lobbardi R, Moore FE, et al. Clonal evolution enhances leukemia-propagating cell frequency in T cell acute lymphoblastic leukemia through Akt/mTORC1 pathway activation. Cancer Cell (2014) 25(3):366-78. doi:10.1016/j.ccr.2014.01.032
78. Scadden DT. Nice neighborhood: emerging concepts of the stem cell niche. Cell (2014) 157(1):41-50. doi:10.1016/j.cell.2014.02.013
79. Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. Nature (2014) 505(7483):327-34. doi:10.1038/nature12984
80. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest (2011) 121(1):396-409. doi:10.1172/JCI35721
81. Ayala F, Dewar R, Kieran M, Kalluri R. Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia (2009) 23(12):2233-41. doi:10.1038/leu.2009.175
82. Pitt LA, Tikhonova AN, Hu H, Trimarchi T, King B, Gong Y, et al. CXCL12-producing vascular endothelial niches control acute T cell leukemia maintenance. Cancer Cell (2015) 27(6):755-68. doi:10.1016/j.ccell.2015.05.002
83. Passaro D, Irigoyen M, Catherinet C, Gachet S, Da Costa De Jesus C, Lasgi C, et al. CXCR4 is required for leukemia-initiating cell activity in T cell acute lymphoblastic leukemia. Cancer Cell (2015) 27(6):769-79. doi:10.1016/j.ccell.2015.05.003
84. Boehm T. Self-renewal of thymocytes in the absence of competitive precursor replenishment. J Exp Med (2012) 209(8):1397-400. doi:10.1084/jem.20121412
85. Martins VC, Busch K, Juraeva D, Blum C, Ludwig C, Rasche V, et al. Cell competition is a tumour suppressor mechanism in the thymus. Nature (2014) 509(7501):465-70. doi:10.1038/nature13317
86. Doulatov S, Notta F, Laurenti E, Dick JE. Hematopoiesis: a human perspective. Cell Stem Cell (2012) 10(2):120-36. doi:10.1016/j.stem.2012.01.006
87. Novershtern N, Subramanian A, Lawton LN, Mak RH, Haining WN, McConkey ME, et al. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell (2011) 144(2):296-309. doi:10.1016/j.cell.2011.01.004
88. Wilkinson AC, Gottgens B. Transcriptional regulation of haematopoietic stem cells. Adv Exp Med Biol (2013) 786:187-212. doi:10.1007/978-94-007-6621-1_11
89. Rieger MA, Schroeder T. Hematopoiesis. Cold Spring Harb Perspect Biol (2012) 4(12):a008250. doi:10.1101/cshperspect.a008250
90. Wadman IA, Osada H, Grutz GG, Agulnick AD, Westphal H, Forster A, et al. The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. EMBO J (1997) 16(11):3145-57. doi:10.1093/emboj/16.11.3145
91. Wilson NK, Foster SD, Wang X, Knezevic K, Schutte J, Kaimakis P, et al. Combinatorial transcriptional control in blood stem/progenitor cells: genome-wide analysis of ten major transcriptional regulators. Cell Stem Cell (2010) 7(4):532-44. doi:10.1016/j.stem.2010.07.016
92. Moignard V, Woodhouse S, Fisher J, Gottgens B. Transcriptional hierarchies regulating early blood cell development. Blood Cells Mol Dis (2013) 51(4):239-47. doi:10.1016/j.bcmd.2013.07.007
93. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell (2005) 122(6):947-56. doi:10.1016/j.cell.2005.08.020
94. Odom DT, Dowell RD, Jacobsen ES, Nekludova L, Rolfe PA, Danford TW, et al. Core transcriptional regulatory circuitry in human hepatocytes. Mol Syst Biol (2006) 2(2006):0017. doi:10.1038/msb4100059
95. Saint-Andre V, Federation AJ, Lin CY, Abraham BJ, Reddy J, Lee TI, et al. Models of human core transcriptional regulatory circuitries. Genome Res (2016) 26(3):385-96. doi:10.1101/gr.197590.115
96. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell (2006) 126(4):663-76. doi:10.1016/j.cell.2006.07.024
97. Batta K, Florkowska M, Kouskoff V, Lacaud G. Direct reprogramming of murine fibroblasts to hematopoietic progenitor cells. Cell Rep (2014) 9(5):1871-84. doi:10.1016/j.celrep.2014.11.002
98. Yui MA, Rothenberg EV. Developmental gene networks: a triathlon on the course to T cell identity. Nat Rev Immunol (2014) 14(8):529-45. doi:10.1038/nri3702
99. Kee BL. E and ID proteins branch out. Nat Rev Immunol (2009) 9(3):175-84. doi:10.1038/nri2507
100. Murre C. Helix-loop-helix proteins and lymphocyte development. Nat Immunol (2005) 6(11):1079-86. doi:10.1038/ni1260
101. Abraham BJ, Hnisz D, Weintraub AS, Kwiatkowski N, Li CH, Li Z, et al. Small genomic insertions form enhancers that misregulate oncogenes. Nat Commun (2017) 8:14385. doi:10.1038/ncomms14385
102. Li Z, Abraham BJ, Berezovskaya A, Farah N, Liu Y, Leon T, et al. APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL. Leukemia (2017). doi:10.1038/leu.2017.75
103. Grutz GG, Bucher K, Lavenir I, Larson T, Larson R, Rabbitts TH. The oncogenic T cell LIM-protein Lmo2 forms part of a DNA-binding complex specifically in immature T cells. EMBO J (1998) 17(16):4594-605. doi:10.1093/emboj/17.16.4594
104. Hsu HL, Wadman I, Baer R. Formation of in vivo complexes between the TAL1 and E2A polypeptides of leukemic T cells. Proc Natl Acad Sci U S A (1994) 91(8):3181-5. doi:10.1073/pnas.91.8.3181
105. Sanda T, Lawton LN, Barrasa MI, Fan ZP, Kohlhammer H, Gutierrez A, et al. Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. Cancer Cell (2012) 22(2):209-21. doi:10.1016/j.ccr.2012.06.007
106. Bain G, Engel I, Robanus Maandag EC, te Riele HP, Voland JR, Sharp LL, et al. E2A deficiency leads to abnormalities in alphabeta T-cell development and to rapid development of T-cell lymphomas. Mol Cell Biol (1997) 17(8):4782-91. doi:10.1128/MCB.17.8.4782
107. Sanda T, Leong WZ. TAL1 as a master oncogenic transcription factor in T-cell acute lymphoblastic leukemia. Exp Hematol (2017) 53:7-15. doi:10.1016/j.exphem.2017.06.001
108. Liau WS, Tan SH, Ngoc PC, Wang CQ, Tergaonkar V, Feng H, et al. Aberrant activation of the GIMAP enhancer by oncogenic transcription factors in T-cell acute lymphoblastic leukemia. Leukemia (2017) 31(8):1798-807. doi:10.1038/leu.2016.392
109. Nitta T, Takahama Y. The lymphocyte guard-IANs: regulation of lymphocyte survival by IAN/GIMAP family proteins. Trends Immunol (2007) 28(2):58-65. doi:10.1016/j.it.2006.12.002
110. Cambot M, Aresta S, Kahn-Perles B, de Gunzburg J, Romeo PH. Human immune associated nucleotide 1: a member of a new guanosine triphosphatase family expressed in resting T and B cells. Blood (2002) 99(9):3293-301. doi:10.1182/blood.V99.9.3293
111. Webb LM, Datta P, Bell SE, Kitamura D, Turner M, Butcher GW. GIMAP1 is essential for the survival of naive and activated B cells in vivo. J Immunol (2016) 196(1):207-16. doi:10.4049/jimmunol.1501582
112. Yano K, Carter C, Yoshida N, Abe T, Yamada A, Nitta T, et al. Gimap3 and Gimap5 cooperate to maintain T-cell numbers in the mouse. Eur J Immunol (2014) 44(2):561-72. doi:10.1002/eji.201343750
113. Chen Y, Yu M, Dai X, Zogg M, Wen R, Weiler H, et al. Critical role for Gimap5 in the survival of mouse hematopoietic stem and progenitor cells. J Exp Med (2011) 208(5):923-35. doi:10.1084/jem.20101192
114. Chadwick N, Zeef L, Portillo V, Boros J, Hoyle S, van Doesburg JC, et al. Notch protection against apoptosis in T-ALL cells mediated by GIMAP5. Blood Cells Mol Dis (2010) 45(3):201-9. doi:10.1016/j.bcmd.2010.07.006
115. Wang H, Zou J, Zhao B, Johannsen E, Ashworth T, Wong H, et al. Genome-wide analysis reveals conserved and divergent features of Notch1/RBPJ binding in human and murine T-lymphoblastic leukemia cells. Proc Natl Acad Sci U S A (2011) 108(36):14908-13. doi:10.1073/pnas.1109023108
116. Ono Y, Fukuhara N, Yoshie O. TAL1 and LIM-only proteins synergistically induce retinaldehyde dehydrogenase 2 expression in T-cell acute lymphoblastic leukemia by acting as cofactors for GATA3. Mol Cell Biol (1998) 18(12):6939-50. doi:10.1128/MCB.18.12.6939
117. Cheung AM, Wan TS, Leung JC, Chan LY, Huang H, Kwong YL, et al. Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia (2007) 21(7):1423-30. doi:10.1038/sj.leu.2404721
118. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell (2007) 1(5):555-67. doi:10.1016/j.stem.2007.08.014
119. Marcato P, Dean CA, Giacomantonio CA, Lee PW. Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle (2011) 10(9):1378-84. doi:10.4161/cc.10.9.15486
120. Appert A, Nam CH, Lobato N, Priego E, Miguel RN, Blundell T, et al. Targeting LMO2 with a peptide aptamer establishes a necessary function in overt T-cell neoplasia. Cancer Res (2009) 69(11):4784-90. doi:10.1158/0008-5472.CAN-08-4774
121. Tanaka T, Sewell H, Waters S, Phillips SE, Rabbitts TH. Single domain intracellular antibodies from diverse libraries: emphasizing dual functions of LMO2 protein interactions using a single VH domain. J Biol Chem (2011) 286(5):3707-16. doi:10.1074/jbc.M110.188193
122. Kwiatkowski N, Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature (2014) 511(7511):616-20. doi:10.1038/nature13393
123. Knoechel B, Roderick JE, Williamson KE, Zhu J, Lohr JG, Cotton MJ, et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat Genet (2014) 46(4):364-70. doi:10.1038/ng.2913